Wilbur J Pan MD PhD
Oncology Clinical Director, Merck & Co.
Join to View Full Profile
Merck & Co.126 E. Lincoln Ave.Rahway, NJ 07065
Phone+1 732-594-3082
Dr. Pan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1994 - 1997
University of Illinois College of MedicineClass of 1994
Certifications & Licensure
NJ State Medical License 2000 - 2025
IL State Medical License 1997 - 2002
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 4 citationsNeoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-5...Rebecca Dent, Javier Cortés, Lajos Pusztai, Heather McArthur, Sherko Kümmel
Journal of the National Cancer Institute. 2024-10-01 - 1 citationsResults from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.Seock-Ah Im, Javier Cortes, David W Cescon, Mastura Md Yusof, Hiroji Iwata
NPJ Breast Cancer. 2024-09-12 - 1 citationsAssociation between event-free survival and overall survival in early-stage triple-negative breast cancer.Min Huang, Peter A Fasching, Amin Haiderali, Weiguang Xue, Wilbur Pan
Future Oncology. 2024-02-01
Journal Articles
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerJavier Cortes, M.D., Ph.D., Hope S. Rugo, M.D., David W. Cescon, M.D., Ph.D., Seock-Ah Im, M.D., Ph.D., Mastura M. Yusof, M.D., Carlos Gallardo, M.D., Oleg Lipatov, M...., New England Journal of Medicine, 7/21/2022
- Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancerMin Huang, Peter Fasching, Amin Haiderali , Wilbur Pan, Emma Gray, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen & Joyce ..., Immunotherapy, 7/7/2022
Press Mentions
East Brunswick Middle School Arts Curriculum Changes Draw PushbackApril 5th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
